Skip to main content

Table 1 Cost breakdown by region

From: Cost-effectiveness of nirsevimab and maternal RSVpreF for preventing respiratory syncytial virus disease in infants across Canada

Strategy

Vaccination costs per infant ($)

Treatment costs per infant ($)

Total costs per infant ($)

South

 No intervention

0

154

154

 PVZ

197

143

341

 NIRS HR

12

138

150

 NIRS HR + MR

40

126

166

 NIRS < 6

429

50

479

 NIRS ALL

467

46

513

 ABR SEASONAL

102

112

214

 ABR SEASONAL + NIRS

141

95

236

 ABR ALL

204

90

294

 ABR ALL + NIRS

243

76

320

Northwest Territories

 No intervention

0

393

393

 PVZ

197

367

564

 NIRS HR

12

355

367

 NIRS HR + MR

40

325

364

 NIRS < 6

429

134

562

 NIRS ALL

467

125

592

 ABR SEASONAL

102

287

389

 ABR SEASONAL + NIRS

141

244

385

 ABR ALL

204

233

437

 ABR ALL + NIRS

243

200

444

Nunavut

 No intervention

0

2305

2305

 PVZ

237

2153

2390

 NIRS HR

14

2075

2090

 NIRS HR + MR

52

1848

1900

 NIRS < 6

429

818

1247

 NIRS ALL

467

771

1238

 ABR SEASONAL

102

1705

1807

 ABR SEASONAL + NIRS

154

1409

1562

 ABR ALL

204

1404

1608

 ABR ALL + NIRS

256

1176

1432

Nunavik

 No intervention

0

1246

1246

 PVZ

234

1146

1380

 NIRS HR

14

1097

1112

 NIRS HR + MR

51

968

1019

 NIRS < 6

429

418

847

 NIRS ALL

467

393

860

 ABR SEASONAL

12

987

999

 ABR SEASONAL + NIRS

153

722

874

 ABR ALL

204

730

934

 ABR ALL + NIRS

255

596

850

  1. ABR RSVpreF, HR high risk, MR medium risk, NIRS nirsevimab, PVZ palivizumab. Optimal strategy in each region is in bold